MAD2L2 and neoplasm: Importantly, VHIO179, a tumour carrying BRCA1 germline truncation, is resistant to treatment with PARP inhibitors due to a MAD2L2 (REV7) inactivating mutation (Bruna et al, 2016; Cruz et al, 2018).